Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione | Zendy

Michael OʼReilly | Zendy; Angela E. Taylor | Zendy; Nicola Crabtree | Zendy; Beverly Hughes | Zendy; Farfia Capper | Zendy; Rachel Crowley | Zendy; Paul M. Stewart | Zendy; Jeremy Tomlinson | Zendy; Wiebke Arlt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione

Author(s) -

Michael OʼReilly,

Angela E. Taylor,

Nicola Crabtree,

Beverly Hughes,

Farfia Capper,

Rachel Crowley,

Paul M. Stewart,

Jeremy Tomlinson,

Wiebke Arlt

Publication year - 2014

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-3399

Subject(s) - androstenedione , polycystic ovary , phenotype , medicine , ovary , endocrinology , metabolic syndrome , biology , insulin resistance , genetics , obesity , androgen , hormone , gene

Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dysfunction in PCOS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research